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Background: Clarithromycin, amoxicillin, and a pump proton inhibitor are the most common drugs recommended
as first-line triple therapy for H.pylori treatment, which results in eradication rates close to 80%, varying regionally,
principally due to emergency cases and increases of clarithromycin resistant strains. Nucleotide substitutions at the
H. pylori domain V of the 23S rRNA fraction are involved in the macrolide resistance and the A2142G and A2143G
mutations are predominant in clinical isolates worldwide including in Brazil. As H. pylori culture is fastidious, we
investigated the primary occurrence of H. pylori A2142G and A2143G rDNA 23S mutations using a molecular
approach directly on gastric biopsies of dyspeptic patients consecutively attended at Hospital das Clinicas of Marilia,
São Paulo, Brazil.
Methods: Biopsy specimens obtained from 1137 dyspeptic patients, were subjected to histopathology and H. pylori
diagnosis by histology and PCR. PCR/RFLP assay was used to detect A2142G and A2143G point mutations at
domain V of the H. pylori 23S rDNA associated with clarithromycin resistance. Through the developed assay, a
768 bp PCR amplicon corresponding to1728 to 2495 bp of the 23S H. pylori rDNA is restricted with MboII for
A2142G mutation detection and with BsaI for A2143G mutation detection. Occurrence of 23S rDNA A2142G results
in two DNA fragments (418 and 350 bp) and of 23S rDNA A2143G results in three DNA fragments (108, 310 and
350pb), due to a conserved BsaI restriction site.
Results: The PCR method used to diagnose H. pylori presented sensitivity, specificity and accuracy of 77,6%, 79,3%
and 78,6%, respectively, compared to histology, the gold standard method for H. pylori diagnosis used in our
routine. Prevalence of H.pylori with clarithromycin resistant genotypes was 2,46%, with predominance of A2143G
23S rDNA point mutation.
Conclusions: The PCR/RFLP assay was a rapid and accurate H.pylori diagnostic and clarithromycin resistance
determination method useful for routine practice. As prevalence of primary resistance of H.pylori to clarithromycin
due to A2142G and A2143G mutations remains low in Marilia, the standard clarithromycin containing triple therapy
is still valid.
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It is widely accepted that Helicobacter pylori, a Gram
negative microaerophylic bacterium, is involved in sev-
eral clinical digestive tract conditions such as chronic
gastritis, peptic and duodenal ulcers, gastric cancer and
lymphoproliferative disorders [1]. Treatment of H. pylori
infection results in ulcer healing and in a reduction of
the risk of gastric cancer and lymphoma [2,3].
Once the bacterium H. pylori is detected in altered gastric
mucosa, the indicated treatment consists of a triple anti-
biotic regimen including methronidazol, clarithromycin,
amoxicillin, tinidazole, tetracycline and fluoroquinolones
associated with a pump proton inhibitor such as omeprazol,
lansoprazol or pantoprazol [4-6]. H. pylori eradication rates
with a number of combined agents and regimens are close
to 80% [7-9], varying from country to country and region-
ally, within countries [10]. Several factors contribute to this
low rate of H. pylori healing including the inefficiency of
the antibiotic penetration in the gastric mucosa, inactiva-
tion of the antibiotic by the acid secretion of the stomach
[11], lack of the patient compliance [12] and principally,
emergency cases and increasing H. pylori antibiotic resistant
strains [13]. Thus, regional H. pylori resistance surveillance
is of great importance for test and treatment strategies.
In Brazil, a country of continental dimensions, themajority
of practicing clinicians employ the classical triple regimen
composed of clarithromycin, amoxicillin and a proton pump
inhibitor for seven days as first line therapy to overcome
H. pylori infection [5,14]. This regimen has been proved to
become inefficient worldwide, mainly as a result of the
emergence and increase of H. pylori strains resistant to
clarithromycin, which reduces the bacterium treatment
efficiency from 55% to 100% [15-18]. Among Brazilian
localities, H. pylori clarithromycin resistance presents high
prevalence, varying from 7-16% in adults [19-22] and 27%
in children [23]. Accordingly, considering the clinical im-
portance of primary H. pylori resistance to clarithromycin,
its prevalence should be considered before choosing
eradication regimens [24].
Determination of H. pylory in vitro susceptibility to anti-
biotics can be performed by standard techniques such as
the agar diffusion, agar dilution and broth microdilution
methods and the E-test. However, because of the slow
growth and the particular requirements of H.pylori culture,
this approach is not reliable for use in most routine clinical
laboratories, principally in developing countries. Hence,
molecular tests targeting H. pylori resistance associated
gene mutations directly from gastric biopsy specimens
have the potential for use in large scale studies [25-29].
The molecular mechanism involved in clarithromycin
resistance consists of mutations in the sequence of the
H. pylori domain V of the 23S rRNA fraction which is
involved in the peptiltransferase ribosome binding site
preventing the ligation of the macrolide to the rRNA[30]. The major characterized point mutations are A to
G at positions 2142 and 2143, A to C at 2142 [31-33], A
to T at 2144 [34], T to C at 2717 [35] and C to A at
2694 [36]. The A2142G and A2143G mutations are
predominant in clinical isolates worldwide including in
Brazil [21,37-40]. Thus, in order to perform a large scale
investigation of clarithromycin primary resistance dir-
ectly from biopsy specimens of 1137 patients attended at
the Hospital das Clínicas of Marilia, a city in the interior
of São Paulo, Brazil, we developed a polymerase chain
reaction associated with restriction fragment length
polymorphism (PCR-RFLP) assay to detect the A2142G
and A2143G nucleotide substitutions at domain V of the
H. pylori 23S rDNA.
Methods
Patients
1137 adult patients resident in Marilia city, São Paulo
State of Brazil, aged 19 to 91 years, who had consecutively
undergone esophagogastroduodenoscopy (EGD) for upper
abdominal pain or dyspeptic symptoms from February
2003 through December 2006 at the gastroenterology
outpatient clinic of the Hospital das Clínicas of Marília
Medical School, were enrolled in this study.
Endoscopy and biopsies
The EGD was accomplished by fibroendoscope (GIF-XP20,
GIF-XQ20) or video-endoscope (GIF-100) both from
Olympus, Shinjuku-ku, Tokyo, Japan. Gastric or duodenal
ulcer diagnostic was defined by endoscopy and two frag-
ments of the antrum were collected to perform the rapid
urease and histopathological tests. The biopsy used for the
rapid urease test was further submitted to DNA extraction.
The protocol used is in agreement with the Helsinki
Declaration and was approved by the Ethical Committee
in Human Research from Marilia Medical School, under
reference number 388/01. In the Ethical Committee ap-
proved research protocol a written informed consent from
each patient included in this study was waived as all gastric
biopsy samples analyzed were the same biopsies used rou-
tinely for urease rapid test as part of the gastroenterology
outpatient service of the Hospital das Clinicas of Marilia
Medical School and thus, no specific patient intervention
was necessary for the enrollment in this proposed study.
Accordingly, waiver of the written informed consent did
not adversely affected the rights and welfare of the subjects
included in this research, and also the confidentiality of the
patients identity was guaranteed.
Histology
One antral specimen was fixed in formol solution at
10% and embedded in paraffin. Sections were Giemsa
stained for H. pylori evaluation and were stained with
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alterations [41].
Polymerase chain reaction, restriction and sequencing
analysis
The same biopsy used for the rapid urease test was sub-
mitted to DNA extraction with the employment of the
GFx DNA extraction kit purchased from Amersham/
Pharmacia Biotech, following the manufacturer’s instruc-
tions. DNA was quantified in agarose gel electrophoresis
using the Invitrogen, Grand Island, New York, USA, low
mass ladder and 50-100ug of total DNA were used in the
PCR reactions with the oligonucleotides: Hp23Sr6 sense
(5′ CACACAGGTAGATGAGATGAGTA3′) and Hp23Sr7
antisense (CACACAGAACCACCGGATCACTA3′), which
amplified a fragment of 768pb corresponding to the do-
main V of the H. pylori 23S rDNA (Figure 1). To over-
come the problems of extensive genetic polymorphism
for precise PCR detection of H.pylori, the oligonucleotide
construction was performed after a comparative analysis
of the 23S rDNA from H.pylori and related organisms
available at Genebank on MegAlign Lasergene software.
PCR condition was 94°C 5′ followed by 40 cycles of 94°C
30″/60°C 30″/72°C 30″ and one cycle at 72°C 7′, with a
total volume of 25 μl containing 1× PCR buffer, 200 μM
dNTPs, 2,0 mM MgCl2, 1 μM of each oligonucleotide,Figure 1 Molecular diagnosis of Helicobacter pylori by PCR and RLFP
and A2143G responsible for clarithromycin resistance. A. Representatio
the primers used for PCR and of the A2142 and A2143 from fraction V of t
BsaI and MboII in PCR fragments containing the mutations A2142G and A2
indicated. B, C and D. Agarose gel stained with ethidium bromide contain
amplicon with MboII and BsaI, respectively. 1–10 correspond to different hu
purchased from Invitrogen. Sizes of the DNA fragments are indicated on th1,25 U Taq DNA Polimerase Platinum Brazil (Invitrogen).
In all PCR reactions a negative and a positive control
were used corresponding to, respectively, sterile water
and H. pylori PCR positive gastric biopsies. The amplified
fragments were digested with MboII and BsaI (New England
Biolabs). These enzymes distinguish mutations in the
H. pylori domain V of the 23S rDNA at the positions 2142
and 2143, respectively. In the presence of A2142Gmutation
the resulting restriction DNA fragments are of 418 bp and
350 bp and in the presence of A2143G mutation the result-
ing fragments are of 108, 310 e 350 bp. As a control of
MboII digestion we used a PCR amplified DNA fragment of
601 bp corresponding to the Leishmania major chitinase
gene that contains a restriction site for MboII. A conserved
BsaI restriction site at the 768 bp PCR amplicon is the
positive control for digestion with this enzyme producing
DNA fragments of 108 and 660 bp in the absence of
A2143G mutation. The products of PCR reactions and
restriction analysis were resolved in 1,5% agarose gels,
stained with ethidium bromide and photographed under
UV light. 23S rDNA 768 bp PCR amplicons from four
gastric biopsies (two positive and two negative for H. pylori
histologic test) with clarithromycin sensitive MboII and
BsaI restriction pattern, and from ten gastric biopsies with
clarytromycin resistant MboII (three samples) and BsaI
(seven samples) restriction patterns were submitted todetection of the domain V of the 23S rRNA mutations A2142G
n of the H. pylori 23S coding gene (Genbank:HPU27270), position of
he 23S rDNA, size of the fragments obtained with restriction enzymes
143G, and internal BsaI restriction site of the 768 bp amplicon, are
ing a PCR diagnostic analysis, restriction analysis of the 768pb
man biopsy specimens; C-, negative control of PCR, M-100 bp ladder
e left or right of each gel figure.
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Ready Reaction kit and an ABI-3100 machine purchased
from Applied Biosystem, according to the manufacturer’s
instructions. Nucleotide sequence determination was per-
formed in duplicate and comparative analysis was carried
out by basic nucleotide BLASTalignment [42].
Statistical analysis
H. pylori diagnostic tests were evaluated by calculating
sensitivity, specificity and accuracy employing histology
as the gold standard.
Results and discussion
This is the first Brazilian large scale study on H. pylori
diagnosis and clarithromycin resistance directly from
biopsy specimens of 1137 consecutive patients submitted
to upper gastroscopy, over a four year period, in a city in
the interior of São Paulo, Brazil.
Gastric disease outcome of all patients enrolled in this
study attended at the gastroenterology outpatient clinic
of Hospital das Clínicas of Marília was investigated by
endoscopy and histopathology. Endoscopic finds of pep-
tic or duodenal ulcer disease (PUD) was present in 123
patients. Different degrees of chronic gastritis (CG) were
observed by histopathology in 706 patients and normal
gastric mucosa, associated or not to gastroesophageal re-
flux disease (GERD) was found in 290 patients. Eighteen
patients were diagnosed as having adenocarcinoma (15)
and MALT lymphoma (3) and were excluded from the
study. Epidemiological analysis, clinical outcome and
H. pylori prevalence of these samples were recently pub-
lished [43].
Detection of H. pylori was performed directly from
biopsy specimens by three different tests: histology, a
household rapid urease test and PCR with the primers
Hp23Sr6/r7 which amplify a 768 bp bacterium fragment
of the domain V of the 23S rDNA. Histology is the gold
standard H.pylori diagnostic test employed in our clinical
routine which together with histopathological analysis is
used to decide for H. pylori eradication therapy. The
household rapid urease test showed a very low positive
predictive value for H. pylori associated gastric diseases
and a high discrepancy when compared to histology;
consequently these data were excluded from the study
(data not shown). The 23S rDNA PCR method detected
H. pylori in 488 gastric biopsies specimens where histology
was positive for 451 biopsies samples. Comparative analysis
of the PCR assay performed with the Hp23Sr6/r7 with
histology showed sensitivity, specificity and accuracy of
77,6%, 79,3% and 78,6%, respectively (Table 1). As both
tests were performed on a single and different biopsy and
H. pylori infection presents a focal characteristic of infection
[44,45], accuracy of 78,6% is acceptable for a trustworthy
diagnostic test. It can be demonstrated by consistence of theH.pylori detection by PCR and histology employed in CG
(53,1% and 52,7%, respectively) and PUD (61,2% and 62,6%,
respectively) patients (Table 1). PCR detected H.pylori in
12,75% in patients with normal gastric mucosa while
histology was positive for only 0,8% of the samples. These
results can be explained by the more sensitive characteris-
tic of the acid nucleic based method. In order to improve
the diagnosis of H.pylori some authors suggest the analysis
of multiple biopsies [44]. In order to confirm the specifi-
city of the PCR fragments obtained, amplicons from two
samples with histologic test for H. pylori positive and
two samples with histologic test for H. pylori negative
were sequenced. BLASTN analysis of all four biopsy
amplified PCR fragments with the 23S rDNA H. pylori
specific primers [Genbank:KF680642, Genbank:KF680643,
Genbank:KF680644 and Genbank:KF680645] revealed iden-
tity of 100% with the 23S rDNA referent to different
strains of H. pylori. Accordingly, the developed PCR assay
is rapid and accurate and can be used as a practical
method for the detection of H.pylori infection.
Antibiotic treatment of gastric diseases is recommended
when H. pylori diagnosis is positive and the bacterium
classic eradication therapy composed of clarithromycin,
amoxicillin and a pump proton inhibitor is prescribed.
The chosen therapy present a high failure of H.pylori
eradication rate in areas where resistance to clarithromy-
cin is higher than 15%, probably in response to the wide-
spread use of this antibiotic for respiratory tract infection,
especially in children [9]. Global primary resistance of
H. pylori to clarithromycin ranges from 1 to 29% [46]. In
Brazil, several studies reported a clarithromycin resistance
prevalence of 7-16% in adults [19,20,22,47] and 27% in
children [23]. Thus, in order to improve the empirical
choice of H.pylori associated disease therapy, we investi-
gated the regional rate of H.pylori clarithromycin resistance
through detection of the major related point mutations,
A2142G and A2143G at domain V of the H. pylori 23S
rDNA.
Thus, all 488H.pylori PCR positive samples were ana-
lyzed by RFLP of the 768 bp PCR fragment obtained with
primers Hp23Sr6/7 with the restriction enzymes MboII and
BsaI, with detect mutations A2142G and A2143G at do-
main V of the H. pylori 23S rDNA, respectively (Figure 1).
Only 12 samples (2,46%) showed the mutated restriction
pattern, three (25%) harboring A2142G mutation, seven
(58,3%) A2143G and one sample (8,7%) showed both
rDNA point mutations in the PCR 23S rDNA 768 bp
fragment. One sample showed partial digestion with the
enzyme MboII (Figure 1). The point mutations A2142G and
A2143G of the amplicons obtained from three [Genbank:
KF680646, Genbank:KF680647 and Genbank:KF680647] and
seven [Genbank:680649, Genbank:680650, Genbank:680651,
Genbank:680652, Genbank:680653, Genbank:680654 and
Genbank:680655] different biopsies samples, respectively,
Table 1 Clinical outcome and comparison of H. pylori diagnostic methods
PUD (n = 123) CG (n = 706) N (n = 290)
His+ His- His+ His- His+ His- T
PCR+ 63 13 76 286 89 375 1 36 37 488
PCR- 14 33 47 86 245 331 1 252 253 631
T 77 46 123 372 334 706 2 288 290 1119
CG chronic gastritis, PUD peptic ulcer disease, N normal gastric mucosa associated or not to gastroesophageal reflux disease (GERD), PCR polymerase chain
reaction, His histology.
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clarithromycin H.pylori resistance point mutations with
patients’ age or gender (data not shown).
The prevalence of H. pylori clarithromycin resistance
found in our region was similar to that found in developed
countries such as Italy and Germany [7] and in the South
American developing country Paraguay [48]. These results
confirm the high regional variability of H.pylori antibiotic
resistance and spite of increasing clarithromycin resistance
worldwide, in Marilia, a low resistance rate was maintained
over the period of four years. Moreover, PCR/RFLP was a
rapid and accurate method for the detection of clarithromy-
cin resistance through a gene mutation directly in gastric
biospsy samples and can be used together with histology
to decide for prescription of clarithromycin containing
regimen therapy.
H. pylori 23S rRNA domain V A2142G and A2143G
point mutations are the major mutations found in H. pylori
clinical isolates resistant to clarithromycin. We found a
higher prevalence of A2143G compared to A2142G muta-
tion in our samples which is in agreement with the majority
of Brazilian studies including the States of Minas Gerais,
São Paulo and Recife [20,34,36]. A2143G but not A2142G
point mutation shows a synergistic effect of clarithromycin
and amoxicillin, which have been used together in the first-
line H. pylori regimen [49], reinforcing the necessity to
investigate this clarithromycin 23S rDNA point mutation
before treatment. One sample harbored both A2142G and
A2143G mutations at domain V of the H. pylori 23S rDNA
that was also found in three H.pylori isolates obtained from
patients of the Brazilian State of Minas Gerais [20]. These
results together with the occurrence of partial digestion
of a 768 bp 23S rDNA PCR fragment (Figure 1) can be
indicative of stomach colonization of multiple strains of
H.pylori [50].
In Minas Gerais, Brazil, clarithromycin resistance has
increased from 4,48% in 1996 to 19,05% in 2000 [20],
probably due to the use of macrolides in the treatment
of other infectious diseases. We did not find any signifi-
cant difference in samples resistant to clarithromycin
according to the period of the study (data not shown).
These data indicate that in our region the prescription
and utilization of macrolides is not performed on a
high scale. More studies are necessary to confirm this
hypothesis.Clarithromycin resistance reduces the clinical efficacy
of clarithromycin-based triple therapy. However, as preva-
lence of primary resistance of H.pylori to clarithromycin
due to the rDNA 23S A2142G and A2143G nucleotide
substitutions remains low in Marilia, the standard clari-
thromycin containing triple therapy is still valid as the
most effective empirical first-line eradication therapy for
H. pylori infection.
Conclusions
The developed PCR assay targeted to the 23S rDNA
gene of H. pylori is rapid and accurate and can be used
as a practical method for the detection of H.pylori infec-
tion directly on gastric biopsy specimens. Furthermore,
the H. pylori 23S rDNA PCR fragment obtained can be
used to detect point mutations from 1728 to 2495 bp of
the H. pylori 23S rDNA domain V associated to clari-
thromycin resistance. Prevalence of primary resistance of
H.pylori to clarithromycin due to 23S rDNA A2142G
and A2143G nucleotide substitutions remains low in
Marilia, thus the standard clarithromycin containing
triple therapy is still valid as the most effective empirical
first-line eradication therapy for H. pylori infection.
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